Alkeus Pharmaceuticals, Inc. announced that Michel Dahan has joined the company as President and Chief Executive Officer and will be responsible for leading the organization’s growth in preparation for commercial launch of its lead asset, gildeuretinol acetate, as a potential treatment for Stargardt disease. Alkeus Co-Founder Leonide Saad, Ph.D., has been named Chief Scientific Officer and will remain an integral part of the company’s continued development of novel treatments for serious diseases of the eye.
“Michel has a depth of biotech experience centered on transforming companies from early stage to commercialization and leading the kind of rapid growth we are experiencing at this point in Alkeus’ evolution,” said Joshua Boger, Ph.D., Chairman of the Alkeus Board of Directors. “Michel’s strategic vision, extensive background and proven company-building capabilities make him an excellent leader to guide Alkeus into the future.”
Dahan joins Alkeus from Akebia Therapeutics, where he served as Senior Vice President and Chief Operating Officer. During his 13-year tenure at Akebia, the company went public, grew from less than 20 employees to more than 400 and raised $1.5 billion in capital. Dahan led the partnering and transactional strategy for Akebia that included completion of several global licensing collaborations, a merger and acquisition in the U.S. with a commercial stage public company, multiple financing deals through equity, debt and royalty monetization.
“I am thrilled to join Alkeus at this pivotal time as we work to gain regulatory approval and bring the first therapy to people living with Stargardt disease in the U.S. as quickly as possible,” Dahan said. “Despite being one of the six most common genetic, autosomal recessive diseases, there is no treatment available for Stargardt, a devastating rare inherited disease that leads to vision loss in children and young adults. We aim to change that, and I am honored to have the opportunity to be part of the important mission of working to make a difference in the lives of Stargardt patients and their families.”
A member of the Alkeus Board since January 2023, Dahan also has served in various roles with biopharma companies, including on the development and commercialization of rare disease therapeutics, and with Ipsen, in business development, global marketing, strategic planning and R&D program leadership. He began his career in investment banking and holds a graduate degree in business administration from HEC Paris (France), a ‘maîtrise’ in mathematics from Sorbonne University (France) and completed the Harvard Business School Program for Leadership Development (PLD).
SOURCE: GlobeNewswire